Development of an Off-the-Shelf Tissue-Engineered Sinus Valve for Transcatheter Pulmonary Valve Replacement: a Proof-of-Concept Study.

Autor: Motta SE; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Fioretta ES; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Dijkman PE; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Lintas V; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland., Behr L; Institute Mutualiste Montsouris (IMMR), Paris, France., Hoerstrup SP; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.; Wyss Translational Center Zurich, University and ETH Zurich, Zurich, Switzerland., Emmert MY; Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland. Maximilian.Emmert@usz.ch.; Wyss Translational Center Zurich, University and ETH Zurich, Zurich, Switzerland. Maximilian.Emmert@usz.ch.; Heart Center Zurich, University Hospital Zurich, Zurich, Switzerland. Maximilian.Emmert@usz.ch.
Jazyk: angličtina
Zdroj: Journal of cardiovascular translational research [J Cardiovasc Transl Res] 2018 Jun; Vol. 11 (3), pp. 182-191. Date of Electronic Publication: 2018 Mar 20.
DOI: 10.1007/s12265-018-9800-6
Abstrakt: Tissue-engineered heart valves with self-repair and regeneration properties may overcome the problem of long-term degeneration of currently used artificial prostheses. The aim of this study was the development and in vivo proof-of-concept of next-generation off-the-shelf tissue-engineered sinus valve (TESV) for transcatheter pulmonary valve replacement (TPVR). Transcatheter implantation of off-the-shelf TESVs was performed in a translational sheep model for up to 16 weeks. Transapical delivery of TESVs was successful and showed good acute and short-term performance (up to 8 weeks), which then worsened over time most likely due to a non-optimized in vitro valve design. Post-mortem analyses confirmed the remodelling potential of the TESVs, with host cell infiltration, polymer degradation, and collagen and elastin deposition. TESVs proved to be suitable as TPVR in a preclinical model, with encouraging short-term performance and remodelling potential. Future studies will enhance the clinical translation of such approach by improving the valve design to ensure long-term functionality.
Databáze: MEDLINE